Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAB-22 pharmacokinetic similarity study versus EU- and US-sourced Prolia in healthy men
NL-OMON60441Phase 1Completed
- Sponsor
- Xentria
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INTP23 and denosumab (3 arms), sponsored by Xentria. Started Jun 2024; status: completed.
02
Drugs
INTP23denosumab
Beyond the preview
Go deeper on NL-OMON60441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60441.